The Thyroid Cancer Diagnostics Market was valued at USD 3.07 Billion in 2024, and is projected to reach USD 4.13 Billion by 2030, rising at a CAGR of 5.30%. The growth of the market is attributed to increasing disease prevalence and the emergence of novel diagnostic products. Although cancer is uncommon worldwide, the incidence rate is on the rise-driven by more sensitive and precise tools to diagnose the disease. It develops as a result of abnormal cell division in the thyroid gland. Since the glandular hormones regulate several functions, such as weight, body temperature, heart rate, and blood pressure, structural or functional anomalies are likely to affect several or all of the aforementioned factors.
Growing awareness and public health initiatives encourage more individuals, especially those at higher risk, to seek screening. This, combined with expanding healthcare infrastructure and increased healthcare spending worldwide, facilitates greater access to advanced diagnostic services. Regulatory support and ongoing research efforts are fostering the introduction of innovative diagnostic solutions, including liquid biopsies and artificial intelligence-driven imaging analysis.
The market has undergone a paradigm shift over the last few years, driven by the introduction of biomarkers and the launch of improved diagnostic products. However, disease progression and recurrence remain high, especially among older patients. Strong unmet needs present a key opportunity to develop breakthrough, first-in-class diagnostics of the disease.
This product will be delivered within 1-3 business days.
Growing awareness and public health initiatives encourage more individuals, especially those at higher risk, to seek screening. This, combined with expanding healthcare infrastructure and increased healthcare spending worldwide, facilitates greater access to advanced diagnostic services. Regulatory support and ongoing research efforts are fostering the introduction of innovative diagnostic solutions, including liquid biopsies and artificial intelligence-driven imaging analysis.
The market has undergone a paradigm shift over the last few years, driven by the introduction of biomarkers and the launch of improved diagnostic products. However, disease progression and recurrence remain high, especially among older patients. Strong unmet needs present a key opportunity to develop breakthrough, first-in-class diagnostics of the disease.
Thyroid Cancer Diagnostics Market Report Highlights
- Papillary carcinoma led the cancer type segment with the largest revenue share of 80.0% in 2024. This is attributed to heightened public awareness, the expansion of screening initiatives, and significant progress in imaging and molecular diagnostic methods, all of which have made it possible to identify cases earlier and with greater accuracy.
- Follicular carcinoma diagnostics is expected to grow at a CAGR of 5.6% over the forecast period, owing to an increased vulnerability among women, a stronger emphasis on prompt diagnosis, and ongoing advancements in diagnostic technologies.
- Imaging technique held the largest revenue share, 36.9%, in 2024, driven by the incorporation of enhanced imaging resolution and artificial intelligence for precise tumor localization and monitoring.
- Biopsy technique is expected to grow at a significant CAGR over the forecast period, owing to advances in biomarker analysis and next-generation sequencing, which have improved diagnostic accuracy and supported individualized care.
- Hospital laboratories accounted for the largest revenue share in 2024. Research institutes are expected to grow at a CAGR of 6.4% from 2025 to 2030.
- North America dominated the global thyroid cancer diagnostics market with the largest revenue share in 2024, primarily driven by the presence of advanced healthcare infrastructure, ongoing awareness campaigns, and access to innovative diagnostic solutions.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Global Thyroid Cancer Diagnostics Market Variables, Trends, & Scope
Chapter 4. Global Thyroid Cancer Diagnostics Market: Cancer Type Business Analysis
Chapter 5. Global Thyroid Cancer Diagnostics Market: Technique Business Analysis
Chapter 6. Global Thyroid Cancer Diagnostics Market: End Use Business Analysis
Chapter 7. Global Thyroid Cancer Diagnostics Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Thyroid Cancer Diagnostics market report include:- Abbott
- F.Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific, Inc.
- Siemens Healthcare GmbH
- Bio-Rad Laboratories, Inc
- GE HealthCare
- Hologic, Inc.
- Koninklijke Philips N.V.
- Toshiba Corporation
- Agilent Technologies, Inc.
- Illumina, Inc.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 100 |
Published | April 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 3.07 Billion |
Forecasted Market Value ( USD | $ 4.13 Billion |
Compound Annual Growth Rate | 5.3% |
Regions Covered | Global |
No. of Companies Mentioned | 12 |